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Introduction
Phthalates are used as plasticizers in soft 
polyvinyl chloride (PVC) and found in a 
large number of commonly used consumer 
products including food, building mate-
rials, plastics, cosmetics, cleaning products, 
packages, and toys (Bornehag et al. 2005; 
Rudel et al. 2011). They are found in indoor 
air (Bergh et al. 2012), dust (Langer et al. 
2014), food, and drinking water (Shi et al. 
2012), and humans are exposed through 
multiple routes. Phthalates are present 
in urine (Frederiksen et al. 2014), blood 
(Frederiksen et al. 2010), and breast milk 
(Fromme et al. 2011) and cross the placental 
barrier (Jensen et al. 2012). A recent state 
of the art report from the World Health 
Organization provides new evidence for 
several human health risks from exposure to 
phthalates and other endocrine disruptors 
(EDCs) including cancer, metabolic outcomes 
(e.g., overweight and obesity), asthma and 
allergy, neurodevelopmental outcomes and 
behavior, as well as reproductive health and 
sexual development (Bergman et al. 2013).
Anogenital distance (AGD; distance from 
anus to genitals) is routinely used in animal 
toxicology studies and is sensitive to anti-
androgenic exposure. In rodents AGD has 
been shown to reflect the amount of androgen 
to which a male fetus is exposed in early devel-
opment; males have longer AGD than females, 
and higher in utero androgen exposure results 
in longer AGD. Numerous studies have shown 
that prenatal phthalate exposure—notably 
DEHP [di(2-ethylhexyl) phthalate], DnBP 
(di-n-butyl phthalate), DiBP (diisobutyl 
phthalate), BBzP (butylbenzyl phthalate)—
shortens male AGD in rodents (Foster 2006; 
Saillenfait et al. 2008). For DiNP animal data 
are much more limited, but shortened male 
AGD has also been reported following prenatal 
exposure to this phthalate (Boberg et al. 2011; 
Clewell et al. 2013; Lee et al. 2006).
Few human studies have been conducted. 
The first American study among 134 mother–
son pairs reported significant association 
between maternal exposure to several phthal-
ates measured in urine and reduced AGD in 
the male offspring (Swan et al. 2005), and a 
later publication found an inverse association 
between maternal urine DEHP exposure and 
AGD and penile size (Swan 2008). Similar 
findings were reported in smaller Japanese 
and Mexican studies (Bustamante-Montes 
et al. 2013; Suzuki et al. 2012). However, 
a small study (n = 33) from Taiwan could 
not confirm the findings (Huang et al. 2009). 
A recent Swedish study found inverse asso-
ciation between maternal urinary DiNP 
metabolites and AGD, which is noteworthy 
given the recent substitution of DiNP for 
DEHP (Bornehag et al. 2014), whereas a 
new U.S. study found association with the 
DEHP metabolites MEHP [mono(2-ethyl-
hexyl) phthalate], MEHHP [mono(2-ethyl-
5-hydroxyhexyl) phthalate] and MEOHP 
[mono(2-ethyl-5-oxohexyl) phthalate] and 
AGD (Swan et al. 2015).
We therefore prospectively investigated 
the association between maternal urinary 
phthalate metabolite concentrations in preg-
nancy and AGD and penile width in the male 
offspring in a sample of 273 mother–son 
pairs in the Odense Child Cohort study.
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Background: Phthalates comprise a large class of chemicals used in a variety of consumer 
products. Several have anti-androgenic properties, and in rodents prenatal exposure has been associ-
ated with reduced anogenital distance (AGD)—the distance from the anus to the genitals in male 
offspring. Few human studies have been conducted, but associations between the anti-androgenic 
phthalates and male AGD have been reported.
oBjective: We aimed to study the association between phthalate exposure in late pregnancy in 
Danish women pregnant in 2010–2012 and AGD in their male infants at 3 months of age (n = 273).
Methods: In the Odense child cohort study, urinary concentrations of 12 phthalate metabolites 
of diethyl, di-n-butyl, diisobutyl, di(2-ethylhexyl), butylbenzyl, and diisononyl phthalate (DEP, 
DnBP, DiBP, DEHP, BBzP, and DiNP, respectively) were measured among 245 mothers of boys 
at approximately gestational week 28 (range, 20.4–30.4) and adjusted for osmolality. AGD, penile 
width, and weight were measured 3 months after the expected date of birth. Associations between 
prenatal phthalate and AGD and penile width were estimated using multivariable linear regression 
adjusting for age and weight-for-age standard deviation score.
results: Phthalate levels were lower in this population than in a recent Swedish study in which 
phthalates were measured in the first trimester. No consistent associations were seen between any 
prenatal phthalate and AGD or penile width. Most associations were negative for exposures above 
the first quartile, and for ln-transformed exposures modeled as continuous variables, but there were 
no consistent dose–response patterns, and associations were not statistically significant (p > 0.05).
conclusion: We found no significant trends towards shorter AGD in boys with higher phthalates 
exposures in this low exposed Danish population.
citation: Jensen TK, Frederiksen H, Kyhl HB, Lassen TH, Swan SH, Bornehag CG, 
Skakkebaek NE, Main KM, Lind DV, Husby S, Andersson AM. 2016. Prenatal exposure to 
phthalates and anogenital distance in male infants from a low-exposed Danish cohort (2010–2012). 
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Methods
Study Settings and Design
The study was based on data from the Odense 
Child Cohort (Kyhl et al. 2015). Briefly, 
newly pregnant women residing in Odense, 
Denmark, between 2010 and 2012 were 
recruited at a voluntary information meeting 
about ultrasound examinations, at first 
antenatal midwife visit, or at the ultrasound 
examination at Odense University Hospital 
at gestational age (GA) 8–16 weeks. Odense 
University Hospital is the only hospital 
in the municipality. Last menstrual period 
was used to calculate the GA (in weeks) of 
all participants. Of the eligible population 
of 6,707 pregnant women, 4,017 women 
were informed about the study and 2,874 
(42.9%) enrolled in the cohort; 2,500 live 
births are being followed up at 3 and 5 years 
of age now. Inclusion criteria were living in 
the municipality of Odense and giving birth 
there. Participants were better educated and 
more often of Danish origin than nonpar-
ticipants (Kyhl et al. 2015). Fasting spot urine 
samples were collected at approximately GA 
28 weeks before 0930 hours and stored in 
freezers at the Odense Patient data Explorative 
Network (OPEN).
Phthalate Measurements
Participants provided a urine sample around 
week 28 of gestation (median 28.7 weeks, 
range 26.4–30.4 weeks of gestation). Samples 
were stored at –80°C until chemical analyses. 
Phthalate metabolite concentrations were 
measured in a subset of 565 women, and 
among these women, 293 women gave birth 
to live-born, singleton boys. We excluded 
women of non-Caucasian origin (n = 15) and 
those with missing information on ethnicity 
(n = 5), leaving 273 pairs of boys and their 
mothers eligible for analyses.
Urine samples were analyzed for total 
content (free and conjugated) of 12 phthalate 
metabolites: monoethyl phthalate (MEP), 
mono-n-butyl phthalate (MnBP), mono-
iso-butyl phthalate (MiBP), monobenzyl 
phthalate (MBzP), MEHP, MEHHP, 
MEOHP, mono(2-ethyl-5-carboxypentyl) 
phthalate (MECPP), mono-iso-nonyl 
phthalate (MiNP), mono-hydroxy-iso-nonyl 
phthalate (MHiNP), mono-oxo-iso-nonyl 
phthalate (MHiOP) and mono-carboxy-
iso-octyl phthalate (MCiOP) by liquid 
chromatography–tandem mass spectrometry 
(LC-MS/MS) with preceding enzymatic 
deconjugation followed by solid phase extrac-
tion. The method for preparation of samples, 
standard solutions, and quality controls as 
well as the instrumental analysis and general 
method validation has previously been 
described in detail (Frederiksen et al. 2010). 
The Chemical Laboratory at Department 
of Growth and Reproduction, Copenhagen 
University Hospital, served as reference labo-
ratory for analysis of phthalate metabolites 
in a European biomonitoring project (http://
www.eu-hbm.info/cophes) and further partic-
ipates yearly in the German External Quality 
Assessment Scheme program (G-EQUAS).
Urinary osmolality, which is a measure 
of urinary dilution, was measured by the 
freezing point depression method using auto-
matic cryoscopic osmometer (Osmomat® 
030; Gonotec, Berlin, Germany). For each 
nine samples, a control standard urine pool 
was measured. Mean urinary osmolality for 
this standard pool (n = 77) was 0.825 Osm/kg 
with a relative standard deviation (RSD) of 
1.85%. The median (range) osmolality of all 
urine samples included in this study was 0.63 
(0.123–1.117) Osm/kg. We used urinary 
osmolality to adjust for urinary dilution. In 
contrast to urinary creatinine adjustment, 
which has the limitation that urinary creati-
nine excretion varies with sex, age, body mass 
index (BMI), fat-free mass, and even ethnicity, 
and urinary specific gravity (which is not 
only influenced by the number of molecules 
in urine but also by their molecular weight 
and size), urine osmolality is directly related 
to the number of particles in solution and is 
unaffected by the molecular weight and size 
of these particles (Frederiksen et al. 2013). In 
subjects with normal renal function, osmolality 
thus reflects an individual’s hydration status.
A total of 565 samples were analyzed: 
196 samples from September 2011 through 
January 2012 (of whom 98 gave birth to a 
boy) (Tefre de Renzy-Martin et al. 2014) and 
369 samples from December 2012 through 
January 2013 (of whom 195 gave birth to a 
boy) (Frederiksen et al. 2014). The first 196 
samples were selected randomly, whereas 
the last 369 were selected based on the 
availability of information from question-
naires, birth records and clinical examina-
tion of the child at 3 months. We observed 
higher levels of some phthalate metabolites 
in the first subset (n = 196, especially DiBP 
metabolites) compared with the second subset 
of samples (n = 369). Therefore, 20 samples 
from each of the first and second subset 
were reanalyzed in the same batch. Similar 
results were obtained by the reanalysis with a 
variation < 5% between the original and the 
 reanalyzed samples.
AGD Measurements
Three months after the expected date of birth, 
regardless of actual gestational age at birth, 
the children were invited to a clinical exami-
nation, which included measurements of 
length, weight, and AGD on 1,659 children, 
of whom 565 mothers had phthalates 
measured in urine, 273 mothers to boys. Two 
different measures of AGD were made using 
a Vernier caliper; the shorter AGD measure-
ment was from the center of anus to the 
posterior base of scrotum (AGDas) and the 
longer from the center of anus to the cephalad 
insertion of the penis (AGDap) measured 
in mm. Penile width was measured at the 
base of the penis using the Vernier caliper 
also (millimeters). In each child, all genital 
measures were repeated three times, and their 
arithmetic mean was calculated. In addition, 
13 boys were measured by two examiners.
Among the 293 women who had phthal-
ates measured in urine and gave birth to a 
boy, the final analyses included 245 (AGDas), 
236 (AGDap) and 241 (penile width) due 
to missing data on AGD measurements or 
covariates. The coefficient of variation (CV) 
was 3% for all the triplicate AGD measure-
ments. Interexaminer CV based on 13 
measurements were, respectively, 4%, 3% and 
4% for AGDas, AGDap, and penile width.
The women provided written consent 
to participate in the study which was 
approved by the local ethical committee. 
The research was conducted in accordance 
with principles of the Declaration of Helsinki 
(declaration of helsinki pdf). 
Data Analysis
Phthalate metabolite concentrations were 
adjusted for urinary osmolality normal-
ized to the median osmolality of all samples 
(0.63 Osm/kg) to correct for urinary dilution. 
This was done for all samples with a measured 
phthalate concentration above the limit of 
detection (LOD) by dividing the individual 
urinary phthalate concentration (nanograms 
per milliliter) with the individual osmolality 
(osmolality per kilogram) of the urine sample 
and multiplying with the median osmolality 
of all samples (0.63 × Osm/kg) (Lassen et al. 
2013). Urinary phthalate concentrations 
below the LOD were not adjusted for osmo-
lality (numbers with levels below the LOD 
can been seen in Table 1), but substituted by 
the phthalate specific LOD divided by the 
square root of 2. To simplify the statistical 
analysis of all DEHP and DiNP metabo-
lites, these were summed by addition of the 
molar sum of the DEHP metabolites (sum 
MEHP + MEHHP + MEOHP + MECPP) 
or the DiNP metabolites (MiNP + MHiNP + 
MOiNP + MCiOP) and expressed as their 
respective parent compound (∑DEHPm or 
∑DiNPm) by multiplication with the molec-
ular weight of DEHP or DiNP, respectively: 
sum of dibutyl phthalate (DBP) isomers 
[ΣDBP(i + n)] and sums of DEHP and DiNP 
metabolites (ΣDEHPm and ΣDiNPm). 
Furthermore, because the two isomers of 
dibutyl phthalate are shown to be highly corre-
lated, their metabolites (MnBP and MiBP) 
were summed [∑MBP(i + n)] in this study for 
additional analysis (Frederiksen et al. 2010).
Phthalate exposure and anogenital distance
Environmental Health Perspectives • volume 124 | number 7 | July 2016 1109
Osmolality-adjusted phthalate metabolites 
[nanograms per milliliter(osm)] were divided 
into quartiles based on the distribution among 
the 273 women (MBzP was divided as levels 
below and above the median because 31% 
were < LOD). These metabolites were also 
entered in the statistical model as a continuous 
variable transformed by use of the natural 
logarithm. The AGD measurements and the 
penile width were left untransformed due to 
acceptable normal distributions of the resid-
uals after visual inspection of histograms and 
normal probability plots. We calculated the 
distribution of ADG as well as the correlations 
(Spearman correlation coefficients) between 
the genital measures. Differences in distribu-
tions of phthalate concentrations according 
to population characteristics were assessed 
by Kruskal–Wallis test. Multivariable linear 
regression analysis was then used to analyze 
the associations between urinary phthalate 
excretion and AGD measurements and penile 
width adjusted for potential confounders. 
Confounders adjusted for in the models were 
factors associated with phthalate concentra-
tions and AGD and or penile width. AGD 
measurements vary with age and weight of 
the child, and because the clinical examina-
tion was scheduled to take place 3 months 
after expected date of birth we constructed 
a measure of postconceptional age defined 
as the sum of gestational age at birth (days) 
and the age of the child at the AGD measure-
ments (days). Analyses of associations between 
phthalate and AGD were thus adjusted for the 
postconceptional age and individual weight-
for-age standard deviation score (z-score) 
(Swan 2008) calculated by use of Danish 
longitudinal growth data (Tinggaard et al. 
2014). We tested trends across quartiles of 
phthalate exposure by inserting ordinal cate-
gorical variable coded using integer values (0, 
1, 2, 3) in the regression. Also, we performed 
the analyses separately among women 
with phthalates measured in 2011–2012 
and 2012–2013.
We evaluated the fit of the regression 
models by inspecting the residual plots for 
model assumption of homogeneity of vari-
ances. SPSS statistics v.19 was used and 
the results are presented with 95% confi-
dence intervals (CIs); p-values < 0.05 were 
 considered significant.
Results
The 565 women with phthalate measurements 
were similar to other women in the cohort 
who delivered singletons with respect to birth 
weight, gestational age at delivery, child sex, 
maternal parity, and age. There were fewer 
smokers, although this was not statistically 
significant (3.4% vs. 5.0%; data not shown). 
The mean age of the women was 30.9 years 
at birth, 57% of the women were nulliparous, 
and 3.4% of the women smoked during preg-
nancy. A total of 9.6% of the mothers reported 
having had infertility treatment; the two AGDs 
in their boys did not differ significantly from 
those of women who did not report treatment 
(data not shown). The boys were examined at 
a median (range) age of 3.3 months (2.3–6.2). 
Median AGDas, AGDap and penile width 
were 36.9 mm (19.4–50.6 mm), 70.2 mm 
(49.1–86.2 mm), and 13.8 mm (10.3–
17.4 mm). Correlation coefficients between 
the two different AGD measures were r = 0.63 
(p < 0.0001). Penile width was weakly, though 
significantly, correlated with AGDas (r = 0.22, 
p < 0.001) and AGDap (r = 0.14, p = 0.03).
All urine samples contained MEP, MiBP, 
or at least one of the DiNP metabolites in 
concentrations above the LOD, which 
means that all women have been exposed to, 
respectively, DEP, DiBP, and DiNP, and 
97%, 96%, and 69% had detectable levels 
of, respectively, DEHP, DnBP, and BBzP 
(Table 1). MiBP was observed in highest 
concentration (median = 27.1 ng/mL) 
followed by MEP and MnBP (Table 1). 
Urine samples were collected across the 
year, and seasonal variation in phthalate 
metabolites was found but with no consis-
tent pattern; some metabolites were higher 
in spring and summer whereas others 
Table 1. Phthalate metabolites [ng/mL(Osm)] measured in gestational week 28 in 273 pregnant Danish 
women (2010–2012).
Diether 
phthalate
Phthalate 
metabolite LOD % > LOD Mean Minimum
Percentiles
Maximum5 25 50 75 95
DEP MEP 0.53 100 102.9 < LODa 2.7 7.2 17.3 54.4 391.7 5380.9
DiBP MiBP 1.10 100 38.5 < LODa 3.7 13.3 27.1 48.2 106.7 371.1
DnBP MnBP 1.43 96 17.8 < LOD 1.5 6.0 12.5 23.0 51.2 184.3
∑MBP(i + n) 56.4 < LOD 5.6 20.4 40.4 75.9 167.8 424.5
BBzP MBzP 1.14 69 6.5 < LOD < LOD 2.6 5.9 16.2 546.0
DEHP MEHP 0.14 89 2.0 < LOD < LOD 0.4 1.2 2.3 5.5 61.1
MEHHP 0.91 91 7.4 < LOD < LOD 2.4 5.2 9.1 19.4 120.8
MEOHP 0.67 93 5.9 < LOD < LOD 2.2 4.4 7.1 14.8 106.4
MECPP 0.55 97 6.9 < LOD 0.8 2.7 5.4 8.7 18.6 88.2
∑DEHPm 29.3 < LOD 1.4 11.4 21.7 36.1 73.0 500.4
DiNP MiNP 0.61 12 0.2 < LOD < LOD 1.2 11.9
MHiNP 0.26 90 5.4 < LOD < LOD 0.7 1.7 4.1 14.2 336.4
MOiNP 0.25 86 2.6 < LOD < LOD 0.4 1.2 2.9 9.2 46.9
MCiOP 0.11 100 9.1 < LODa 0.5 2.0 3.9 9.3 24.7 196.4
∑DiNPm 22.9 < LOD 0.7 4.3 9.0 22.5 67.3 476.1
∑MBP(i + n), sum of MiBP and MnBP. ∑DEHPm, molar sum of DEHP metabolites expressed as excreted DEHP (ng/mL). 
∑DiNPm, molar sum of DiNP metabolites expressed as excreted DiNP (ng/mL). 
aLess than 1% were below LOD.
Table 2. Median maternal osmolality adjusted urinary phthalate excretion of ∑MBP(i + n), ∑DiNPm, and 
∑DEHPm [ng/mL(osm)] according to maternal characteristics.
Maternal characteristics na ∑MBP(i + n) ∑DEHPm ∑DiNPm
All 267
Maternal age at delivery (years)
< 25 29 43.1 23.6 8.9
25–29 92 40.3 21.2 10.6
30–34 90 43.4 21.1 7.6
≥ 35  56 48.3 26.1 12.7
Prepregnancy BMI (kg/m2)
< 20 26 44.7* 24.0* 7.0*
20–25 142 38.8* 21.4* 8.6*
≥ 25  99 51.1* 25.7* 12.6*
Parity
Nulliparous 154 44.2* 22.0 9.0
Multiparous 113 42.8* 22.2 10.9
Maternal smoking during pregnancy
Yes 9 110.4* 44.7* 19.0*
No 258 43.0* 21.6* 9.2*
Preterm birth (before week 37)
Yes 9 43.5 20.4 19.0
No 258 43.7 22.2 9.4
Birth weight (g)
< 2,500 6 43.5 20.0 18.1
2,500–3,999 200 44.1 22.9 9.2
≥ 4,000  61 41.2 21.1 9.8
∑MBP(i + n), sum of MiBP and MnBP. ∑DEHPm, molar sum of DEHP metabolites expressed as excreted DEHP (ng/mL). 
∑DiNPm, molar sum of DiNP metabolites expressed as excreted DiNP (ng/mL).
a267 participants included in the table due to missing data. *p < 0.05, Kruskal–Wallis test.
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were higher in autumn and winter (data 
not shown).
The analyses were performed with MEP, 
MiBP, MnBP, ∑MBP(i + n), MBzP, ∑DiNPm 
and ∑DEHPm. ∑MBP(i + n), ∑DiNPm, 
and ∑DEHPm were higher in women with 
high or low BMI and among women who 
smoked (Table 2). The analyses were there-
fore initially adjusted for smoking and BMI, 
which changed the estimates < 10% (data 
not shown). Adjustment for parity did also 
changed the estimates < 10%.
No dose-dependent association between 
any phthalate metabolites and AGD or penile 
width was found either in unadjusted or in 
adjusted analyses (Table 3), as observed by 
the lack of monotonic patterns or significant 
trends, or in the model for the continuous 
exposures. Interestingly, however, almost all 
estimates were negative, suggesting that AGD 
and penile width were shorter in boys with 
exposures above the first quartile than in boys 
with exposures below the 25th percentile.
Mean AGDas was lower for boys in the 
second, third, and fourth quartiles of MEP 
compared with boys in the first quartile 
[–0.64 mm (95% CI: –2.52, 1.23 mm), 
–1.68 mm (95% CI: –3.56, 0.20 mm), 
and –1.37 mm (95% CI: –3.27, 0.54 mm), 
respectively], though differences were not 
statistically significant (Table 3). Maternal 
∑DiNPm and ∑DEHPm levels in the second, 
third, and fourth quartiles were associated 
with shorter AGD in the boys compared with 
levels in the first quartile. Exposure levels in 
the third quartile were associated with shorter 
AGDas than in the fourth quartile [–1.24 
(–3.21, 0.73) vs. –0.29 (–2.17, 1.59) and 
–1.25 (–3.17, 0.67) vs. –1.16 (–3.08, 0.77)].
Discussion
In this prospective study among 245 mother–
son pairs, no dose–response association 
between maternal phthalate exposure and 
AGD or penile width in the male offspring 
was found. The exposure levels before adjust-
ment in our cohort’s women were lower 
than in some previous studies (Table 4). 
Interestingly, median concentrations of all 
phthalate metabolites were about two to 
four times lower in our study than were 
levels observed in a recent Swedish study 
(Bornehag et al. 2014) in which both labora-
tories participated in the same quality-control 
program project, and the Danish laboratory 
served as reference laboratory (Schindler 
et al. 2014). Compared with the American 
study of future families from 1999 through 
2002 the Danish levels were also lower for 
DEP, BBzP, and DEHP but higher for 
both DiBP and DnBP (Swan et al. 2005). A 
new U.S. study found higher levels of DEP 
and DEHP metabolites, but lower levels of 
DBP metabolites compared with our study 
(Swan et al. 2015) (Table 4), whereas the 
levels in three smaller studies were compa-
rable with ours. In addition, except for the 
MBzP metabolites, all phthalate metabolites 
were measurable in > 95% of the samples 
in our study, the Swedish study and the 
two U.S. studies. In the U.S. and Swedish 
studies, the women delivered urine samples 
in first trimester, whereas we collected urine 
samples in second and third trimester. 
There is limited information about changes 
in phthalates over the course of pregnancy, 
but two studies have reported decreases in 
DEHP levels during pregnancy (Braun et al. 
2012; Ferguson et al. 2014). A single spot 
urine sample may reasonably classify MEP 
and MBP concentrations during pregnancy, 
but more than one sample may be necessary 
for MBzP and DEHP (Adibi et al. 2008; 
Braun et al. 2012). In addition, the Swedish 
study collected morning urine samples, in 
which phthalate levels may be higher than 
in spot urines because phthalate levels peak 
2–8 hr after intake (Frederiksen et al. 2013). 
Table 3. Association between short AGD (AGDas), long AGD (AGDap), and penile width in boys and 
quartiles of osmolality-adjusted concentrations of or continuous ln-transformed phthalate metabolites 
in prenatal urine expressed as a β-coefficient (expressing the change in mm) (95% CI) from an adjusteda 
linear regression model.
Phthalate metabolite [ng/mL(osm)] 
(quartile) AGDas (n = 245) AGDap (n = 236) Penile width (n = 241)
MEP
1st (LOD–8.9) Reference Reference Reference
2nd (9.0–19.9) –0.64 (–2.52, 1.23) –0.33 (–2.37, 1.72) –0.08 (–0.49, 0.43)
3rd (20.0–54.9) –1.68 (–3.56, 0.20) –0.24 (–2.32, 1.85) –0.28 (–0.70, 0.13)
4th (≥ 55) –1.37 (–3.27, 0.54) –0.96 (–3.01, 1.15) –0.07 (–0.49, 0.34)
p-Trendb 0.09 0.41 0.52
Continuousc –0.34 (–0.84, 0.17) 0.02 (–0.54, 0.58) 0.03 (–0.09, 0.14)
MiBP
1st (LOD–16.9) Reference Reference Reference
2nd (17.0–29.9) –0.68 (–2.58, 1.22) 0.14 (–1.93, 2.21) –0.29 (–0.70, 0.13)
3rd (30.0–49.9) –0.66 (–2.49, 1.18) –0.92 (–2.93, 1.09) –0.35 (–0.75, 0.05)
4th (≥ 55) –0.55 (–2.49, 1.39) –0.88 (–2.99, 1.22) –0.25 (–0.67, 0.16)
p-Trendb 0.57 0.27 0.19
Continuousc –0.03 (–0.90, 0.83) –0.11 (–1.07, 0.84) –0.13 (–0.32, 0.05)
MnBP
1st (LOD–7.9) Reference Reference Reference
2nd (8.0–13.9) 1.18 (–0.73, 3.01) 0.19 (–1.88, 2.27) –0.22 (–0.63, 0.20)
3rd (14.0–20.9) –1.07 (–2.89, 0.76) –1.37 (–3.36, 0.63) –0.31 (–0.71, 0.08)
4th (≥ 55) 0.19 (–1.66, 2.04) –0.07 (–2.14, 2.00) –0.19 (–0.60, 0.22)
p-Trendb 0.60 0.56 0.28
Continuousc –0.13 (–0.89, 0.63) –0.27 (–1.10, 0.56) –0.04 (–0.21, 0.12)
MBzPd
1st (LOD–2.49) Reference Reference Reference
2nd (≥ 2.5) –0.80 (–2.13, 0.54) –0.72 (–2.19, 0.75) 0.06 (–0.24, 0.35)
p-Trendb 0.24 0.34 0.70
Continuousc –0.42 (–1.06, 0.21) –0.27 (–0.97, 0.43) –0.03 (–0.17, 0.11)
∑MBP(i + n)
1st (LOD–24.9) Reference Reference Reference
2nd (25.0–43.9) 0.44 (–1.45, 2.32) 0.32 (–1.74, 2.37) –0.53 (–0.94, –0.12)
3rd (44.0–69.9) –0.95 (–2.89, 0.98) –0.97 (–3.08, 1.14) –0.40 (–0.82, 0.02)
4th (≥ 70) –0.11 (–2.04, 1.82) –0.69 (–2.82, 1.43) –0.41 (–0.83, 0.00)
p-Trendb 0.56 0.31 0.12
Continuousc –0.08 (–0.94, 0.78) –0.16 (–1.10, 0.77) –0.10 (–0.29, 0.08)
∑DiNPm
1st (LOD–4.9) Reference Reference Reference
2nd (5.0–9.9) –0.88 (–2.75, 0.98) –0.21 (–2.27, 1.86) –0.07 (–0.48, 0.33)
3rd (10.0–19.9) –1.24 (–3.21, 0.73) 0.08 (–2.06, 2.22) –0.29 (–0.72, 0.14)
4th (≥ 20) –0.29 (–2.17, 1.59) 0.99 (–1.05, 3.03) 0.05 (–0.36, 0.45)
p-Trendb 0.74 0.31 0.98
Continuousc –0.15 (–0.75, 0.44) 0.22 (–0.42, 0.87) –0.02 (–0.15, 0.11)
∑DEHPm
1st (LOD–13.9) Reference Reference Reference
2nd (14.0–21.9) –1.05 (–2.95, 0.85) –1.17 (–3.26, 0.93) 0.06 (–0.36, 0.48)
3rd (22.0–33.9) –1.25 (–3.17, 0.67) –0.51 (–2.61, 1.59) 0.09 (–0.33, 0.51)
4th (≥ 34) –1.16 (–3.08, 0.77) –0.45 (–2.56, 1.66) 0.04 (–0.39, 0.46)
p-Trendb 0.25 0.86 0.84
Continuousc –0.47 (–1.35, 0.41) –0.33 (–1.29, 0.63) 0.07 (–0.13, 0.26)
aAdjusted for the postconceptional age (defined as the sum of gestational age at birth and the age of the child at 
the AGD measurements) and individual weight for age standard deviation score (z-score). bp-Value for trend across 
quartiles of phthalate exposure inserting ordinal categorical variable. cLn-transformed osmolality adjusted phthalate 
concentration. dMBzP were divided as levels below and above medians because 31% were < LOD.
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Our women were fasting, however, and their 
samples were collected before 0930 hours, 
so it is unlikely that phthalate intake from 
breakfast would have been excreted. The 
differences in phthalate levels between our 
study and the Swedish study may be partly 
attributed to differences in timing of urine 
collection as well as differences in lifestyle and 
consumer behavior factors that may affect 
phthalate exposure.
Swan et al. (2005) found associations 
between shorter male AGD and prenatal 
exposure, particularly for DEHP metabolites, 
in U.S. mothers recruited in 1999–2002 
and among mothers recruited 2010–2012 
(Swan et al. 2015), a period during which 
levels declined (Table 4); the Swedish study 
among 196 boys recruited 2009–2010 
reported stronger association between AGD 
and DiNP than DEHP and DEP metabo-
lites (Bornehag et al. 2014). During this 
10-year period DEHP has been replaced 
by DiNP in soft PVC applications. Three 
smaller studies have been published (Table 4) 
(Bustamante-Montes et al. 2013; Huang et al. 
2009; Suzuki et al. 2012); two found asso-
ciation between MEHP and “total phthalate 
levels” and AGD, whereas one did not find 
any association between prenatal phthalate 
exposure and AGD. However, the latter was 
conducted among 33 Taiwanese women with 
high-risk pregnancies scheduled for amniocen-
tesis (Huang et al. 2009) and MEP exposure 
levels were low (as in our study).
Phthalate exposure in Denmark has 
declined considerably during the past 
10 years (Frederiksen et al. 2014). Our 
findings of considerably lower phthalate 
levels in Danish pregnant women than in 
Swedish women confirms the findings from a 
previous European Union coordinated study 
(Den Hond et al. 2015).
DEHP and DiNP are known to be anti-
androgens in rodent studies, although DiNP is 
less potent (Foster 2006; Hannas et al. 2011), 
and DiNP has replaced DEHP in soft PVC 
because of similar properties. Rats’ exposure 
to DiNP during gestation and perinatally 
has been found to increase the incidence of 
reproductive malformations in male offspring 
and to cause alterations in fetal testicular 
testosterone production (Borch et al. 2004). 
Conflicting results between prenatal exposure 
to DiNP and AGD in male rats have been 
found: Some studies found reduced AGD 
(Boberg et al. 2011; Clewell et al. 2013; Lee 
et al. 2006) whereas others found no associa-
tion (Gray et al. 2000; Masutomi et al. 2004). 
This may be attributable to differences in 
exposure levels between studies.
AGD measurements are well toler-
ated by all subjects and quick to perform, 
with < 5% intra- and interexaminer reli-
ability, and currently few known factors 
need to be controlled for (age and body 
size). AGD measurements differ consider-
ably among studies (Bornehag et al. 2014; 
Bustamante-Montes et al. 2013; Huang et al. 
2009; Suzuki et al. 2012; Swan et al. 2005; 
Thankamony et al. 2014), which may partly 
be explained by differences in age at examina-
tion. Some studies measured only one AGD 
Table 4. Characteristics of cohort studies measuring AGD and distribution (median and 25–75 percentiles) of unadjusted/raw urinary levels (ng/mL) of phthalate 
metabolites.
Study characteristics
Odense child 
cohort  
(Kyhl et al. 2015)
Study of future 
families  
(Swan et al. 2005)
SELMA study 
(Bornehag et al. 2014)
TIDES  
(Swan et al. 2015)
Japanese study 
(Suzuki et al. 2012)
Mexican study 
(Bustamante-
Montes et al. 
2013)
Women 
undergoing 
amniocentesis 
(Huang et al. 2009)
Country and year Denmark, 
2010–2012
USA, 1999–2002 Sweden, 2008–2009 USA, 2010–2012 Japan, 2005–2006 Mexico, ND Taiwan, 
2005–2006
Trimester of urine 
sampling
2nd and 3rd 2nd and 3rd 1st 1st 2rd 3rd 1st
Number of participants 245 134 196 753 111 73 33
AGD measurements 3 months 15 months 19–21 months At birth At birth At birth At birth
Findings No associations MBP ≥ AGDap↓
MEP ≥ AGDap↓
MiBP ≥ AGDap↓
DiNP metabolites 
≥ AGDas↓
MEHP ≥ AGDas↓ 
MEOHP ≥ AGDas↓
MEHHP ≥ AGDas↓
MEHP ≥ AGDap↓ “Total phthalate” 
≥ AGDap↓
No associations
β-value multivariable 
linear regression for 
positive findings
Ln MEP
β = –0.34, 
p = 0.36
Log MBP, MEP, MiBP
–0.59, p = 0.03
–0.40, p = 0.02
–0.77, p < 0.01
Log SumDiNP
β = –1.69, p = 0.05
Log MEHP, MEOHP, 
MEHHP
–1.12, p = 0.04
–1.43, p < 0.01
–1.28, p = 0.01
Log MEHP
β = –0.23, p = 0.02
“Total phthalate”
β = –0.19, 
p = 0.04
Adjustment Weight-adjusted 
AGD, post-
conceptional age
Weight-adjusted 
AGD, maternal age
Age, gestational week 
of sampling, weight for 
age, creatinine
Age, gestational age, 
z-score, time of urine 
collection, maternal 
age, study center
Smoking, 
gestational 
week, birth order, 
maternal age
Birth length, 
creatinine
Gestational age
Phthalate metabolite (ng/mL) 
before adjustment
MEP 17.3 (7.2–54.4) 128.4 (53.3–436.9) 60.6 (30.7–134.1) 26.0 (9.0–81.0) 7.8 (3.4–31.7) 7.6 ± 12.7a 19.1 (4.9–324.4)b
MnBP 27.1 (13.3–48.2) 13.5 (7.2–30.9) 66.0 (43.1–111.8) 7.0 (2.5–16.6) 7.0 (ND–16.6) 0.7 ± 0.5a 79.6 (28.1–232.6)b
MiBP 12.5 (6.0–23.0) 2.5 (0.7–5.1) 4.4 (1.6–10.6)
MBzP 2.6 (0–5.9) 8.3 (3.5–23.5) 15.1 (7.9–35.6) 3.1 (1.0–9.0) 3.6 (1.2–8.7) 0.6 ± 0.2a 2.5 (0–13.9)b
MEHP 1.2 (0.4–2.3) 3.3 (1.3–9.0) 3.3 (1.9–5.9) 2.0 (0.7–4.7) 3.7 (2.1–7.1) 4.0 ± 4.2a 26.3 (11.9–120.3)b
MEHHP 5.2 (2.4–9.1) 11.4 (6.0–20.1) 15.3 (8.7–22.9) 6.1 (2.4–14.0) 7.1 (4.2–13.8)
MEOHP 4.4 (2.2–7.1) 11.1 (5.1–19.0) 10.0 (5.7–15.6) 4.4 (2.0–9.9) 7.8 (4.4–13.0)
MECPP 5.4 (2.7–8.7) 14.5 (8.0–22.5) 8.6 (3.4–18.8)
∑DEHPmc 55.6 (29.2–92.4) 148.1 (84.6–220.7) 75.0 (28.2–165.0)
MHiNP 1.7 (0.7–4.1) 6.3 (2.8–14.2)
MOiNP 1.2 (0.4–2.9) 2.8 (1.3–6.2)
MCiOP 3.9 (2.0–9.3) 8.3 (5.0–16.4) 13.2 (5.0–45.2)
∑DiNPmd 21.4 (10.3–53.7) 55.9 (28.3–124.9)
Urine Fasting, spot urine Spot urine Morning urine Spot urine Spot urine Spot urine Spot urine
Adjustment Osmolality None Creatinine Specific gravidity Specific gravidity Creatinine Creatinine
ND, no dates found.
aMean ± SD, MEHP, MBzP, MEP and MBP detectable in 67%, 14%, 11% and 12%. bMedian (10th–90th percentile). c∑DEHPm, molar sum of DEHP metabolites 
(MEHP + MEHHP + MEOHP + MECPP) (nmol/L) in all studies. d∑DiNPm, molar sum of DiNP metabolites (MHiNP + MOiNP + MCiOP) (nmol/L) in all studies.
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distance whereas others measured both the 
AGDas and the distance to the AGDap. 
The AGDas is less dependent on infant size; 
nevertheless the U.S. study found stronger 
associations for AGDap (Swan et al. 2015).
AGD is a continuous measure of devel-
opmental exposure to anti-androgens in 
rodents (Foster 2006). Because it can be 
measured in all boys it is a more sensitive 
marker of genital development than the birth 
prevalence of cryptorchidism or hypospadias, 
which are found in < 10% of newborns, thus 
requiring large study populations. Shorter 
AGD has been associated with hypospadias 
and cryptorchidism in human males (Hsieh 
et al. 2008; Thankamony et al. 2014). In 
male rodents, shortened AGD persists into 
adulthood (Hotchkiss et al. 2004) and 
predicts compromised reproductive function 
(reduced testis size) in the mature male 
(Scott et al. 2008). The same link between 
prenatal anti-androgen exposure and adult 
reproductive function is suggested by cross-
sectional studies among adult men, which 
have found associations between AGD and 
adult semen quality (Eisenberg et al. 2011; 
Mendiola et al. 2011) and serum testosterone 
(Eisenberg et al. 2012a). In addition, fertile 
men and men with obstructive azospermia 
(suggested to be caused by infections) have 
a longer AGD than infertile men and those 
with nonobstructive azospermia (Eisenberg 
et al. 2011, 2012b). This suggests that 
shortened AGD may be a member of the 
symptom complex of the testicular dysgenesis 
syndrome (TDS) (Thankamony et al. 2014). 
This is also in line with the theory that TDS 
symptoms result from a disturbance in the 
Sertoli cell and Leydig cell differentiation 
during fetal life, leading to impaired testos-
terone production and decreased virilization 
(Skakkebæk 2004).
Our study has several strengths: It is 
large and is population based because the 
municipality only included one hospital. 
However, only 42% of the eligible women 
participated, and 1,659 had AGD measured; 
also, participants were better educated than 
nonparticipants. Their age at delivery resem-
bled that of pregnant women in Denmark, 
and the women had no knowledge of their 
phthalate exposure or the AGD of their child 
at enrollment. It is therefore unlikely to have 
affected their participation. In addition, we 
compared women across phthalate exposure, 
so whether they represented the general 
population is therefore of less importance 
in the study except for generalizability. We 
adjusted for relevant confounders, but we 
cannot exclude the possibility of residual 
confounding by other factors associated with 
phthalate exposure and growth measures, 
such as co-exposure to other environmental 
 chemicals, lifestyle, or health behavior.
Phthalates are quickly metabolized 
with a urinary excretion half-life of < 24 hr 
(Anderson et al. 2001, 2011; Koch et al. 
2012). A single spot urine sample collected 
around gestational week 28 may therefore not 
reflect fetal exposure in the sensitive devel-
opmental window; however, a single spot 
urine sample may reasonably classify MEP 
and MBP concentrations during pregnancy, 
but more than one sample may be necessary 
for MBzP and DEHP (Adibi et al. 2008; 
Braun et al. 2012). The women were fasting, 
which may contribute to the low urine 
phthalate levels. However, this misclassifica-
tion is likely nondifferential because it is not 
associated with AGD and thus may under-
stimate the effect of phthalate exposure. In 
addition, temporal and seasonal variation in 
phthalate levels in our study population was 
found (data not shown), though samples were 
collected during the whole calendar year (data 
not shown). Also, phthalates were measured 
in two different batches; however, we reas-
sessed 20 samples, and acceptable agreement 
between original and later levels were found.
Conclusions
In conclusion, in this population based 
study of 245 mother–son pairs we found no 
consistent dose–response association between 
maternal phthalate exposure and AGD in the 
offspring. Phthalate exposure was low in this 
population: ≤ 50% of that in a recent Swedish 
study and lower than in U.S. studies (except 
for the DnBP isomers) conducted 1999–2002 
and 2010–2012. They, however, measured 
phthalate levels in first trimester, and the 
Swedish study used morning urine whereas 
we measured fasting spot urine in second and 
third trimester, which may explain some of 
the differences in exposure levels.
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